cannabis Related Content

OCD symptoms could be eased by atleast half in the short-term, according to a new study published in the Journal of Affective Disorders.

Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains CBG (cannabigerol), a “new” cannabinoid with vast potential in cannabis research.

In early 2016, I had reached a point in life where I needed to make a life-changing decision: Read the Savage Cabbage journey on OAG.

Here, we talk to Professor Trevor Jones at the European Medical Cannabis Association (EUMCA) about storing CBD, clinical trials post-Brexit and the UK-US trade deal.

CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.

Here, Evolve Ltd’s Managing Director, Christopher Busuttil Delbridge, takes us progressively deeper into what it takes to ensure regulatory compliance for Medical Cannabis.

Hannah Deacon, co-founder of Maple Tree Consultancy, explores how COVID is elevating and shaping the medical application of CBD.

Here, Professor Mike Barnes discusses and answers some key questions about the world of CBD in the UK.

Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.

Here, we learn how Mile High Labs, a leading processor of hemp-derived cannabinoids, have raised Series B equity financing and are preparing for global CPG partnerships.

Kathleen Denoodt continues to enlighten us on the subject of medical cannabis, particularly imports to Germany and the Netherlands.

A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.

Associate, David Hardstaff and Partner, John Binns at BCL Solicitors LLP, explain here how cannabis wonder child takes a knock in light of the European Commission’s ‘pause’ on CBD novel food applications mean for this booming industry.

Janosch Kratz discusses the importance of medical cannabis for chronic pain diseases.

Chair of the European Medicinal Cannabis Association (EUMCA) issues warning that raising limit for THC in CBD to 0.3% will risk patient safety.

Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.

Dr Daniela Tonucci, a consultant for over 10 years, talks us through the use of cannabinoids as pain medicine.

Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.

David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.

Here, we learn how about a different kind of green crop that grows in Ireland and the journey of that from seed to shelf as part of the Greenheart CBD story.